Under the terms of the collaboration, Laboratory Corporation of America Holdings (LabCorp) will be Vanda’s exclusive commercialization partner for tests for genetic markers of the Fanapta program.
Vanda has identified a series of pharmacogenetic markers during its development of Fanapta, and the company continues its work in this area.
Andrew Conrad, chief scientist and global head of clinical trials for LabCorp, said: “This collaboration is an example of our commitment to the advancement of personalized medicine and represents a successful translation of a research-based assay into a valuable diagnostic test. This relationship is consistent with our focus on companion diagnostics.”